Cardinal Health (CAH)
(Delayed Data from NYSE)
$102.58 USD
+1.92 (1.91%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $102.37 -0.21 (-0.20%) 6:52 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$102.58 USD
+1.92 (1.91%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $102.37 -0.21 (-0.20%) 6:52 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
Zacks News
Quanterix (QTRX) Expands in Alzheimer's Testing With Alliances
by Zacks Equity Research
Quanterix's (QTRX) blood-based biomarker testing offers a superior alternative, aligning with the recommendations of the NIA-AA criteria for AD diagnosis.
Henry Schein (HSIC) Q4 Earnings Miss, Operating Margin Down
by Zacks Equity Research
Henry Schein (HSIC) posts lower-than-expected earnings and revenues in the fourth quarter of 2023.
Best Growth Stocks to Buy for February 27th
by Zacks Equity Research
POWL, CAH and TXT made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 27, 2023.
Momentum Monday: Bull Market Continues
by Ethan Feller
Want to start the week ahead of the pack? Check out Momentum Mondays
Here's Why You Should Buy Edward Lifesciences (EW) Stock Now
by Zacks Equity Research
Investors are optimistic about Edward Lifesciences' (EW) progress with the Structural Heart business and strong TAVR potential.
Penumbra (PEN) Q4 Earnings Top Estimates, Margins Increase
by Zacks Equity Research
Penumbra's (PEN) Q4 revenues register year-over-year growth driven by robust U.S. thrombectomy sales.
ClearPoint Neuro (CLPT) Gets FDA's Nod for New Software
by Zacks Equity Research
ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to provide fast, peri-procedural segmentation of the cortical structures of the brain.
Here's Why You Should Add Lantheus (LNTH) to Your Portfolio
by Zacks Equity Research
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
Bruker's (BRKR) New Launches Drive Growth Amid FX Woes
by Zacks Equity Research
Bruker's (BRKR) revenues continue to be driven by the strength of end markets, including academic and government, and industrial.
Philips' (PHG) New Innovation to Boost Radiation-Free Imaging
by Zacks Equity Research
Philips (PHG) announces its latest LumiGuide imaging technology, which is likely to pave the way for new radiation-free procedures. It will prove beneficial for complex aortic surgeries.
Here's Why Investors Should Hold Labcorp (LH) Stock for Now
by Zacks Equity Research
Targeted development in high-growth areas and strategic partnerships bode well for Labcorp (LH).
Charles River (CRL) Forges Collaboration With Wheeler Bio
by Zacks Equity Research
Charles River (CRL) and Wheeler Bio join forces to accelerate the journey from discovery and CMC development to manufacturing.
Amedisys' (AMED) Q4 Earnings Miss Estimates, Margins Up
by Zacks Equity Research
The continuous shortage of clinical labor, nursing in particular, is likely to have impacted Amedisys' (AMED) Q4 performance.
BD (BDX), Camtech Health Unite to Aid Cervical Cancer Screening
by Zacks Equity Research
BD (BDX) collaborates with Camtech Health to improve the rate of cervical cancer screening in Singapore by offering women an option to self-collect samples in the privacy of their own homes.
Lantheus (LNTH) Q4 Earnings Surpass Estimates, Gross Margin Up
by Zacks Equity Research
Lantheus' (LNTH) robust segmental revenues drive its fourth-quarter performance.
3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio for Now
by Zacks Equity Research
Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.
Teleflex (TFX) Q4 Earnings Top Estimates, Operating Margin Falls
by Zacks Equity Research
Teleflex (TFX) surpasses earnings and revenue estimates in the fourth quarter of 2023.
Best Growth Stocks to Buy for February 23rd
by Zacks Equity Research
CAH, POWL and PAX made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 23, 2024.
Best Value Stocks to Buy for February 23rd
by Zacks Equity Research
BLDR and CAH made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 23, 2024.
Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands
by Zacks Equity Research
Veracyte's (VCYT) fourth-quarter 2023 performance reflects solid financial discipline and the strength of the Decipher Prostate and Afirma tests.
Best Income Stocks to Buy for February 23rd
by Zacks Equity Research
AROC, JSAIY and CAH made it to the Zacks Rank #1 (Strong Buy) income stocks list on February 23, 2024.
New Strong Buy Stocks for February 23rd
by Zacks Equity Research
IRDM, JSAIY, CAH, LNTH and CENTA have been added to the Zacks Rank #1 (Strong Buy) List on February 23, 2024.
ICON (ICLR) Q4 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
ICON's (ICLR) solid performance in the fourth quarter reflects continued market leadership across customer segments it serves.
Better Therapeutics' (BTTX) CBT Gains FDA's Breakthrough Status
by Zacks Equity Research
Better Therapeutics' (BTTX) novel CBT platform attains the FDA's breakthrough device designation to improve patient care in the treatment of liver and metabolic diseases.
Nevro's (NVRO) Q4 Earnings and Sales Top Estimates, Margins Up
by Zacks Equity Research
Nevro's (NVRO) fourth-quarter earnings and revenues surpass their respective consensus estimate. The company incurs a loss in the operating level.